Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.